Nehama Zuckerman Levin

Nehama Zuckerman Levin

Auto-generated profile, based on publicly available information

Nehama Zuckerman Levin

Institute of Diabetes, Endocrinology and Metabolism, Rambam Health Care Center, Bruce Rappaport Faculty of Medicine, Technion , Haifa 31096

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
SGShira Goldman
Shira Goldman
OPOrit Pinhas-Hamiel
Orit Pinhas-Hamiel
AWAdi Weinberg
Adi Weinberg
AAAdi Auerbach
Adi Auerbach
AGAlina German
Alina German
YLYael Lebenthal
Yael Lebenthal
Objective To evaluate the incidence and severity of ketoacidosis (DKA) at type 1 diabetes diagnosis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic in Israel. Research Design and Methods A population-based study the product of a national collaboration of Israeli pediatric diabetes centers investigated the presentation of childhood-onset type 1 diabetes. The frequencies of DKA and severe DKA observed during the COVID-19 period from March 15, 2020 (commencement of the first nationwide lockdown) until June 30, 2020 were compared with the same periods in 2019, 2018, and 2017 using multivariable logistic regression, adjusting for age, sex, and socioeconomic position. Results During the COVID-19 period, DKA incidence was 58.2%, significantly higher than in 2019 (adjusted OR [aOR] 2.18 [95% CI, 1.31-3.60], P = 0.003); 2018 (aOR 2.05 [95% CI, 1.26-3.34], P = 0.004); and 2017 (aOR, 1.79 [95% CI,1.09-2.93], P = 0.022). The incidence of severe DKA was 19.9%, significantly higher than in 2018 (aOR, 2.49 [95% CI, 1.20-5.19], P = 0.015) and 2017 (aOR, 2.73 [95% CI,1.28-5.82], P = 0.009). In 2020, admissions and duration of stay in the intensive care unit were higher than in previous years (P = 0.001). During the COVID-19 pandemic, children aged 6-11 years had higher incidences of DKA (61.3% vs 34.0%, 40.6%, and 45.1%, respectively, P = 0.012), and severe DKA (29.3% vs 15.1%, 10.9%, and 5.9%, respectively, P = 0.002). Conclusions The dramatic increase in DKA at presentation of childhood-onset type 1 diabetes during the COVID-19 pandemic mandates targeted measures to raise public and physician awareness.

Verified
Journal Article
Open access
PDF file
YLYael Lebenthal
Yael Lebenthal
ABAvivit Brener
Avivit Brener
EHEli Hershkovitz
Eli Hershkovitz
NSNaim Shehadeh
Naim Shehadeh
SSShlomit Shalitin
Shlomit Shalitin
MRMarianna Rachmiel
Marianna Rachmiel
Our aim was to assess the efficacy, safety, and tolerability of alpha-1 antitrypsin (AAT) as a therapeutic modality for β-cell preservation in patients with recent-onset type 1 diabetes. Seventy type 1 diabetes patients (37 males; mean age 13.1 ± 4.1years) were randomized to treatment with 22 infusions of AAT (Glassia®) (60 or 120 mg/kg) or placebo. The primary outcome was the area under the curve (AUC) of C-peptide from a 2-h mixed-meal tolerance test after 52 weeks. At week 52, C-peptide was 0.9, 0.45, and 0.48 pmol/mL in the AAT-120, AAT-60, and placebo groups (p = 0.170 and p = 0.866 vs. placebo, respectively). The declines in C-peptide glycated hemoglobin (HbA1c) and the total insulin dose (U/kg) were similar across groups. Within the predefined 12–18-years subgroup, the C-peptide AUC decreased significantly in the placebo and AAT-60 groups (−0.34 and −0.54 pmol/mL, respectively, p < 0.01), with a borderline decrease in the AAT-120 group (−0.29 pmol/mL, p = 0.047). The mean HbA1c level was significantly lower in the AAT-120 group compared to the placebo (6.7% ± 0.9% vs. 8.2 ± 1.4%, p = 0.05), and a higher percentage of patients attained HbA1c ≤ 7% (75% vs. 25%, p = 0.05). AAT was tolerated well, with a similar safety profile between groups. The AAT intervention showed promise in the subgroup of adolescents with recent-onset type 1 diabetes. Further studies are warranted to determine the impact and proposed mechanism of action of AAT in β-cell preservation.

25 October 2013 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
NZN. Zuckerman‐Levin
N. Zuckerman‐Levin
ZHZ. Hochberg
Z. Hochberg
YLY. Latzer
Y. Latzer

1 June 2022 in Pediatric Diabetes
Verified
Journal Article
Closed access
NLNehama Zuckerman Levin
Nehama Zuckerman Levin
MCMeidan Cohen
Meidan Cohen
MPMoshe Phillip
Moshe Phillip
ATAriel Tenenbaum
Ariel Tenenbaum
IKIlana Koren
Ilana Koren
NSNaim Shehadeh
Naim Shehadeh

13 September 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
AJAnders Juul
Anders Juul
PBPhilippe Backeljauw
Philippe Backeljauw
MHMichael Højby
Michael Højby
JFJan Frystyk
Jan Frystyk
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
RHReiko Horikawa
Reiko Horikawa
Context: Somapacitan, a once-weekly reversible albumin-binding growth hormone (GH) derivative, is evaluated in short children born small for gestational age (SGA). Objective: Evaluate efficacy, safety, tolerability as well as total and bioactive insulin-like growth factor I (IGF-I) response of once-weekly somapacitan compared to daily GH in children born SGA. Methods: REAL5 is a randomized, multicenter, open-label, controlled phase 2 study comprising a 26-week main phase, a 26-week extension, and an ongoing 4-year safety extension (NCT03878446), conducted at 38 sites across 12 countries. A total of 62 GH-treatment-naïve, prepubertal short children born SGA were randomized; 61 completed 52-weeks of treatment. Patients were randomized (1:1:1:1:1) to somapacitan (0.16, 0.20, or 0.24 mg/kg/week) or daily GH (0.035 or 0.067 mg/kg/day), all administered subcutaneously. Results: Estimated mean height velocity (HV; cm/year) at week 52 was 8.5, 10.4, and 10.7 cm/year for somapacitan 0.16, 0.20, and 0.24 mg/kg/week, respectively, and 9.3 and 11.2 cm/year for daily GH 0.035 and 0.067 mg/kg/day, respectively. Dose-dependent increases in total IGF-I, as well as peak IGF-I bioactivity, were observed for both treatments and were similar between comparator groups. For somapacitan, exposure-response modeling indicated highest efficacy with 0.24 mg/kg/week after 52 weeks of treatment. Similar safety and tolerability were demonstrated across all groups. Conclusion: A sustained dose-dependent growth response was demonstrated for somapacitan after 52 weeks of treatment. Overall, somapacitan 0.24 mg/kg/week provides similar efficacy, safety, and tolerability, as well as comparable bioactive and total IGF-I response, as daily GH (0.067 mg/kg/day) in children born SGA.

14 June 2019 in Journal of Advanced Nursing
Verified
Journal Article
Closed access
PDF file
EDEfrat Dagan
Efrat Dagan
Ilana DuboviIlana Dubovi
Ilana Dubovi
MLMilana Levy
Milana Levy
NLNehama Zuckerman Levin
Nehama Zuckerman Levin
SLSharona T. Levy
Sharona T. Levy